Habaruje

Pubmed: Drugs »

  • Drugs AND (hasabstract[text] AND "last 5 years"[PDat]); +338 new citations

    Posted 2017-06-22 10:00:50 dun: Mahammad A. Tafida

    338 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Drugs AND (hasabstract[text] AND "last 5 years"[PDat]) These pubmed results were generated on 2017/06/22PubMed comprises more than millions of citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web ...

    Volde: 0   'Beddu...

  • Drugs AND (hasabstract[text] AND "last 5 years"[PDat]); +349 new citations

    Posted 2017-06-21 22:00:29 dun: Mahammad A. Tafida

    349 new pubmed citations were retrieved for your search. Click on the search hyperlink below to display the complete search results: Drugs AND (hasabstract[text] AND "last 5 years"[PDat]) These pubmed results were generated on 2017/06/21PubMed comprises more than millions of citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web ...

    Volde: 0   'Beddu...

  • (19)F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors.

    Posted 2017-06-20 22:00:54 dun: Mahammad A. Tafida

    Related Articles (19)F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors. ACS Med Chem Lett. 2017 Jun 08;8(6):632-635 Authors: Skora L, Jahnke W Abstract In modern kinase drug discovery, allosteric inhibitors have become a focus of attention due to their potential selectivity, but such compounds are difficult to identify. Here we describe an NMR-based competition assay using (19)F-containing reporter molecules, which allows for rapid identification and discrimination between ATP-competitive and allosteric kinase inhibitors. We illustrate the principle of such a dual-site competition assay with the example of catalytic and allosteric ABL1 kinase inhibitors. The assay can also be used to identify and characterize mixed binding modes of well-known drugs, as shown for crizotinib and fingolimod. PMID: 28626524 ...

    Volde: 0   'Beddu...

  • Where Are Drugs Invented, and Why Does It Matter?

    Posted 2017-06-20 22:00:54 dun: Mahammad A. Tafida

    Related Articles Where Are Drugs Invented, and Why Does It Matter? ACS Med Chem Lett. 2017 Jun 08;8(6):589-591 Authors: Friedman Y Abstract Globalization has disrupted many industries, initially shifting unskilled labor employment from high wage-cost industrialized nations to lower wage-cost emerging economies. There has been a trend toward moving increasingly skilled work away from industrialized nations, which raises the question-has innovative research and development been affected by globalization, and why is relocation of innovation much more than a simple economic concern? PMID: 28626514 ...

    Volde: 0   'Beddu...

  • Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea.

    Posted 2017-06-20 22:00:54 dun: Mahammad A. Tafida

    Related Articles Rate of Adverse Events and Healthcare Costs Associated with the Topical Treatment of Rosacea. Am Health Drug Benefits. 2017 May;10(3):113-119 Authors: Williamson T, Kamalakar R, Ogbonnaya A, Zagadailov EA, Eaddy M, Kreilick C Abstract BACKGROUND: Rosacea is a condition more common in women than in men, and in people aged ≥30 years than in younger patients. Adverse events associated with the use of topical medications for rosacea may lead to a lack of treatment adherence. Previous studies have reported low treatment adherence rates among patients with rosacea. OBJECTIVE: To describe the rate of treatment discontinuation resulting from adverse events and the associated healthcare costs among patients with rosacea who are receiving a topical medication. METHODS: We conducted a retrospective cohort study of patients diagnosed with rosacea based on International Classification of Diseases, Ninth Revision, Clinical Modification code 695.3 who were newly initiating topical treatment with metronidazole, azelaic acid, sodium sulfacetamide/sulfur, or benzoyl peroxide between January 1, 2009, and September 30, 2013. Patients were identified from the MarketScan Commercial Claims and Encounters database and the Medicare Supplemental database and had to be aged ≥30 years, have continuous coverage with medical and pharmacy benefits ≥12 months before treatment and ≥3 months after treatment inititation, and have no evidence of oral antibiotic use or ocular rosacea during the study period. The 3-month period immediately after the index date (ie, first topical rosacea treatment) was defined as the postindex period and was used to evaluate the outcome measures, which included the rate of adverse events, treatment patterns, and healthcare costs. RESULTS: The final cohort included 49,351 patients, with a mean age of 54 years, and 74.5% of the patients were female. Metronidazole was the ...

    Volde: 0   'Beddu...